Keros Therapeutics Files Proxy Statement with Glass Lewis Recommendation
Ticker: KROS · Form: DEFA14A · Filed: May 27, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | DEFA14A |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting, governance
TL;DR
Keros proxy filing out, Glass Lewis is on board. Vote your shares!
AI Summary
Keros Therapeutics, Inc. filed a DEFA14A proxy statement on May 27, 2025, which includes a press release announcing a recommendation from Glass Lewis & Co. The filing is related to the company's upcoming annual meeting and likely concerns proposals to be voted on by shareholders.
Why It Matters
This filing is important for shareholders as it provides information and recommendations from a proxy advisory firm, influencing how they might vote on company matters at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would inherently increase risk.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- Glass Lewis & Co. (company) — Proxy advisory firm
- 0001104659-25-052890 (filing_id) — Accession Number
FAQ
What is the purpose of this DEFA14A filing?
The purpose of this DEFA14A filing is to provide shareholders with a proxy statement, which includes information and recommendations from Glass Lewis & Co. regarding matters to be voted on at Keros Therapeutics, Inc.'s annual meeting.
When was this filing made?
This filing was made on May 27, 2025.
Who is Glass Lewis & Co. in relation to Keros Therapeutics?
Glass Lewis & Co. is a leading independent proxy advisory firm that has made a recommendation concerning Keros Therapeutics, Inc.
What is the standard industrial classification for Keros Therapeutics?
The standard industrial classification for Keros Therapeutics is Pharmaceutical Preparations [2834].
What is the business address of Keros Therapeutics?
The business address of Keros Therapeutics is 1050 Waltham Street, Suite 302, Lexington, MA 02421.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 27, 2025 regarding Keros Therapeutics, Inc. (KROS).